Trials / Unknown
UnknownNCT05133453
Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Cairo University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study aims at determining the the efficiency and prognosis of using pirfenidone drug among asbestosis patients.
Detailed description
Asbestos exposure is associated with pleural and lung fibrosis and lung cancer. It has pathomechanisms and clinical similarities to interstitial pulmonary fibrosis disease. There is no definite cure for asbestosis. Pirfenidone has antifibrotic and anti-inflammatory effects.The safety and effectiveness of pirfenidone for the treatment of non-interstitial pulmonary fibrosis progressive fibrotic interstitial lung diseases remain unclear including asbestosis. Only few studies for pirfenidone use in asbestosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone | drug intake three times daily for one year |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2025-02-01
- Completion
- 2026-02-01
- First posted
- 2021-11-24
- Last updated
- 2023-08-30
Source: ClinicalTrials.gov record NCT05133453. Inclusion in this directory is not an endorsement.